London’s PolyModels Hub, a startup innovating the digital transformation of biopharma course of growth, has raised €7.9 million (£7 million) in a Sequence A spherical to develop its engineering and product groups, improve its core platform, and attain extra pharmaceutical organisations worldwide.
The spherical was led by Molten Ventures, with participation from Marathon Enterprise Capital.
“The pharmaceutical business is present process a once-in-a-generation digital transformation. In simply 18 months, our expertise and distinctive group have delivered tangible worth throughout a number of programmes, increasing these collaborations to a worldwide scale,” says Antonio Benedetti, CEO & co-founder, PolyModels Hub.
PolyModels Hub’s increase is a part of a broader development in 2025, the place digital and BioTech software program options are more and more attracting funding.
As an illustration, ScienceMachine, a London-based AI-driven BioTech information evaluation startup, secured €2.9 million for product growth. Equally, Kiin Bio, additionally based mostly in London, raised €1.9 million to launch a digital scientist platform for drug discovery. In the meantime, in Sweden, Cellcolabs raised €10.3 million to scale industrial‑scale stem-cell manufacturing, and EnsiliTech from the UK secured €5.2 million to scale back cold-chain prices in biopharma logistics.
Mixed, these corporations characterize a complete funding of round €20 million, additional demonstrating rising curiosity within the intersection of digital innovation and the life sciences sector in Europe.
PolyModels Hub’s increase is particularly vital because it highlights the rising demand for scalable, data-driven infrastructure in biopharma R&D and manufacturing.
“We’re investing deeply in complicated biologics and advancing our platform to empower scientists with the model-based options they deserve to rework molecules into medicines for the twenty first century,” provides Benedetti.
Based in 2023, PolyModels Hub is a BioTech software program firm creating the digital spine for biopharma course of growth. Its flagship platform, ModelFlow, integrates information, fashions, and workflows to assist scientists and engineers design, simulate, and optimise pharmaceutical processes quicker and extra reliably.
In line with the corporate, creating a brand new drug sometimes prices round €2.8 billion ($2.5 billion), with roughly 1 / 4 of that – about €738 million ($650 million) – spent on course of growth alone. Throughout the tons of of therapies progressing by means of the pipeline annually, this represents an unlimited alternative to make drug growth quicker, extra environment friendly, and extra reproducible.
Their platform, ModelFlow, brings collectively superior modeling, simulation, and workflow administration in a single built-in digital atmosphere. It permits scientists and engineers to design, take a look at, and refine manufacturing processes quicker, connecting information and experience throughout groups and departments.
Ben Wilkinson, CEO, Molten Ventures, provides: “PolyModels Hub is fixing an actual ache level for pharma groups, bringing collectively deep area experience and cutting-edge expertise in a approach that’s genuinely transformative. We’re proud to help Antonio B, Antonio Y, Harry and the group as they scale their affect throughout the business.
“What impressed us most is the group’s mix of technical know-how and deep understanding of their prospects’ challenges. They’ve constructed an answer that delivers worth in weeks, not years, and its speedy adoption throughout the business speaks volumes.”
In typical settings, scientists depend on dozens and even tons of of laboratory experiments to optimise a single course of – work that may take weeks or months to finish.
In early deployments, ModelFlow has reportedly diminished experimental workloads by greater than 90%, turning 100-experiment workflows into fewer than ten whereas sustaining or bettering scientific robustness.
These outcomes communicate to a broader shift underway throughout the business. Pharmaceutical groups are recognizing that course of growth is not only a technical step, however a strategic lever for pace, high quality, and regulatory success. As manufacturing turns into extra complicated – spanning small molecules, biologics, and rising modalities – the necessity for scalable, data-driven infrastructure is just rising.
“Regardless of the technological and scientific progress, a big a part of pharma nonetheless runs on archaic lab processes, delaying sufferers’ entry to life-changing medicines. We’re privileged to be day one companions with PolyModels Hub as they redefine how the business designs, exams, and improves drug growth processes utilizing information and automation”, stated Alex Alexakis, Companion, Marathon Enterprise Capital.
